Cambridge Cognition Holdings appoint Stephen Symonds as CFO and Francesca Cormack as Chief Scientist

Cambridge Cognition Holdings plc (LON: COG), which develops and markets digital solutions to assess brain health, has announced two senior management appointments.

Stephen Symonds has joined the Company as its new Chief Financial Officer and is expected to join the board in due course.  Stephen is an experienced finance professional and was until recently the Chief Financial Officer of Envigo, a private equity backed provider of pre-clinical services for the pharmaceutical industry, where he spent eight years.  Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.  Earlier in his career, he built a broad experience in a variety of small to medium-size accounting companies and as the finance lead in a family-owned business.

The board would like to thank Nick Walters for providing Cambridge Cognition Holdings with interim financial leadership while the Chief Financial Officer recruitment process was conducted.

Francesca Cormack has been appointed as the Company’s Chief Scientist, having spent seven years at Cambridge Cognition, most recently as Director of Research and Innovation.  Francesca will lead the Company’s research and development activities and act as the Company’s scientific leader, with a view to enhancing its competitive position and supporting its long-term business success.  She is also an honorary senior research fellow at Cambridge University’s department of psychiatry.

Jenny Barnett, currently Chief Scientific Officer, will be stepping down from the Company at the end of April 2022 to focus her efforts on Monument Therapeutics.  Monument Therapeutics was spun out from Cambridge Cognition in July 2021 and continues to work closely with the Company using its cognitive assessments as core elements of their developments.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition 25% growth in revenues to £12.6 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 ·         Revenue ahead of

Cambridge Cognition Holdings

Cambridge Cognition acquires Winterlight Labs Inc

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis.  The total consideration for the Acquisition is

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022. The Company followed its strong performance in 2021 with a 31%

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

Cambridge Cognition Holdings

Cambridge Cognition to announce preliminary results on 12 April 2022

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will announce its preliminary results for the year ended 31 December 2021 on 12 April 2022. Cambridge Cognition is a technology company developing digital

No more posts to show